Laura, cada vez que vienes al @cniostopcancer.bsky.social descubrimos facetas nuevas de ti, de omomyc y de tu trayectoria como emprendedora. Eres un ejemplo y una inspiración para todos!
Estamos atentos a los ensayos clínicos de #Peptomyc!!!
@vhio.bsky.social
Estamos atentos a los ensayos clínicos de #Peptomyc!!!
@vhio.bsky.social
Ayer, 3 de diciembre, participé como ponente en la XV edición del @cniostopcancer.bsky.social Lab Day, contando mi experiencia científica y emprendedora en @vhio.bsky.social, @icreacommunity.bsky.social y #Peptomyc. Muchas gracias a los estudiantes por invitarme! @msmelanoma.bsky.social
December 4, 2025 at 8:47 PM
Laura, cada vez que vienes al @cniostopcancer.bsky.social descubrimos facetas nuevas de ti, de omomyc y de tu trayectoria como emprendedora. Eres un ejemplo y una inspiración para todos!
Estamos atentos a los ensayos clínicos de #Peptomyc!!!
@vhio.bsky.social
Estamos atentos a los ensayos clínicos de #Peptomyc!!!
@vhio.bsky.social
Honored to deliver a keynote today at the 19th Scientific Day & 29th Annual Conference of Vall d’Hebron on collaborative, challenge-driven research with transformative health impact. #MYC #OMO-103 #Omomyc
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc
December 4, 2025 at 7:56 PM
Honored to deliver a keynote today at the 19th Scientific Day & 29th Annual Conference of Vall d’Hebron on collaborative, challenge-driven research with transformative health impact. #MYC #OMO-103 #Omomyc
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc
Our work MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer has been accepted in
@cp-cellreports.bsky.social : 🚀
@cp-cellreports.bsky.social : 🚀
December 3, 2025 at 6:56 AM
Our work MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer has been accepted in
@cp-cellreports.bsky.social : 🚀
@cp-cellreports.bsky.social : 🚀
🔴 A #VHIO-led study led by Laura Soucek and Fabio Giuntini shows that combining the MYC inhibitor #Omomyc (by VHIO & @icreacommunity.bsky.social's #Peptomyc) the with DNA-repair–targeted therapies boosts anti-tumor activity in preclinical triple-negative #BreastCancer.
➡️ linke.to/OmomycVHIO
➡️ linke.to/OmomycVHIO
MYC targeting by Omomyc synergizes with PARP inhibition and potentiates antitumor response in preclinical models of trip
linke.to
December 2, 2025 at 11:51 AM
🔴 A #VHIO-led study led by Laura Soucek and Fabio Giuntini shows that combining the MYC inhibitor #Omomyc (by VHIO & @icreacommunity.bsky.social's #Peptomyc) the with DNA-repair–targeted therapies boosts anti-tumor activity in preclinical triple-negative #BreastCancer.
➡️ linke.to/OmomycVHIO
➡️ linke.to/OmomycVHIO
Enhorabuena Laura Soucek por la subvención #ProofOfConcept de @ERC_research para el proyecto #SONOMYC ‼️
🎯 Con el objetivo de optimizar la administración del inhibidor de #MYC, Omomyc en el cerebro para tratar tumores cerebrales y metástasis 👉 https://linke.to/ERCLauraSoucek_VHIOCAST
#ERCPoC
🎯 Con el objetivo de optimizar la administración del inhibidor de #MYC, Omomyc en el cerebro para tratar tumores cerebrales y metástasis 👉 https://linke.to/ERCLauraSoucek_VHIOCAST
#ERCPoC
July 14, 2025 at 10:25 AM
Enhorabuena Laura Soucek por la subvención #ProofOfConcept de @ERC_research para el proyecto #SONOMYC ‼️
🎯 Con el objetivo de optimizar la administración del inhibidor de #MYC, Omomyc en el cerebro para tratar tumores cerebrales y metástasis 👉 https://linke.to/ERCLauraSoucek_VHIOCAST
#ERCPoC
🎯 Con el objetivo de optimizar la administración del inhibidor de #MYC, Omomyc en el cerebro para tratar tumores cerebrales y metástasis 👉 https://linke.to/ERCLauraSoucek_VHIOCAST
#ERCPoC
Un estudi coliderat per la #investigadoraICREA Laura Soucek @lsoucek.bsky.social (@lsouceklab.bsky.social) mostra que Omomyc —fàrmac creat per la spin-off d'ICREA i VHIO Peptomyc— pot ser una estratègia terapèutica per combatre el càncer de mama triple negatiu.
🔗Consulta la notícia: bit.ly/4pRdY6P
🔗Consulta la notícia: bit.ly/4pRdY6P
Un estudi liderat per Laura Soucek i Fabio Giuntini #VHIO mostra que combinar l’inhibidor de MYC Omomyc (del Peptomyc, VHIO &
@icreacommunity.bsky.social spin-off) amb teràpies dirigides a la reparació de l’ADN potencia l’activitat antitumoral en #càncerdemamatriplenegatiu
➡️ linke.to/OmomycVHIO_Cat
@icreacommunity.bsky.social spin-off) amb teràpies dirigides a la reparació de l’ADN potencia l’activitat antitumoral en #càncerdemamatriplenegatiu
➡️ linke.to/OmomycVHIO_Cat
Combinar l’inhibidor de MYC Omomyc amb teràpies dirigides a la reparació de l’ADN potencia la resposta antitumoral en mo
linke.to
December 4, 2025 at 9:07 AM
Un estudi coliderat per la #investigadoraICREA Laura Soucek @lsoucek.bsky.social (@lsouceklab.bsky.social) mostra que Omomyc —fàrmac creat per la spin-off d'ICREA i VHIO Peptomyc— pot ser una estratègia terapèutica per combatre el càncer de mama triple negatiu.
🔗Consulta la notícia: bit.ly/4pRdY6P
🔗Consulta la notícia: bit.ly/4pRdY6P
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
Giuntini et al. demonstrate that Omomyc, the only direct MYC inhibitor currently in phase 2 clinical trials, causes DNA damage and synergizes with PARPis in triple-negative breast cancer. Their findings provide compelling evidence for clinical exploration of this combination to overcome PARPi resistance.
dlvr.it
December 5, 2025 at 12:23 AM
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
#AACR25 | On Tuesday, April 29, at @theaacr.bsky.social, Fabio Giuntini, researcher in VHIO’s Models of Cancer Therapies Group, will present on how Omomyc synergizes with PARPi and reverts resistance to therapy in multiple PARPi-resistant triple-negative breast cancer models.
April 27, 2025 at 11:01 AM
#AACR25 | On Tuesday, April 29, at @theaacr.bsky.social, Fabio Giuntini, researcher in VHIO’s Models of Cancer Therapies Group, will present on how Omomyc synergizes with PARPi and reverts resistance to therapy in multiple PARPi-resistant triple-negative breast cancer models.
Interesting paper by the group of @sebastianpomplun.bsky.social of our @led3hub.bsky.social. Chemical stapling of recombinant proteins on the example of the Myc inhibitor Omomyc leads to enhanced serum stability, cellular uptake and intracellular activity.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
ReCHEMbinant stapling enhances intracellular delivery and bioactivity of engineered protein inhibitors
Protein therapeutics have transformed drug discovery by enabling modulation of challenging targets inaccessible to small molecules. However, most prot…
www.sciencedirect.com
December 18, 2025 at 11:26 AM
Interesting paper by the group of @sebastianpomplun.bsky.social of our @led3hub.bsky.social. Chemical stapling of recombinant proteins on the example of the Myc inhibitor Omomyc leads to enhanced serum stability, cellular uptake and intracellular activity.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.
December 3, 2025 at 6:56 AM
In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.
Link to the article: www.cell.com/cell-reports...
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
Giuntini et al. demonstrate that Omomyc, the only direct MYC inhibitor currently in
phase 2 clinical trials, causes DNA damage and synergizes with PARPis in triple-negative
breast cancer. Their findin...
www.cell.com
December 3, 2025 at 6:56 AM
Link to the article: www.cell.com/cell-reports...
Un estudi liderat per Laura Soucek i Fabio Giuntini #VHIO mostra que combinar l’inhibidor de MYC Omomyc (del Peptomyc, VHIO &
@icreacommunity.bsky.social spin-off) amb teràpies dirigides a la reparació de l’ADN potencia l’activitat antitumoral en #càncerdemamatriplenegatiu
➡️ linke.to/OmomycVHIO_Cat
@icreacommunity.bsky.social spin-off) amb teràpies dirigides a la reparació de l’ADN potencia l’activitat antitumoral en #càncerdemamatriplenegatiu
➡️ linke.to/OmomycVHIO_Cat
Combinar l’inhibidor de MYC Omomyc amb teràpies dirigides a la reparació de l’ADN potencia la resposta antitumoral en mo
linke.to
December 2, 2025 at 11:51 AM
Un estudi liderat per Laura Soucek i Fabio Giuntini #VHIO mostra que combinar l’inhibidor de MYC Omomyc (del Peptomyc, VHIO &
@icreacommunity.bsky.social spin-off) amb teràpies dirigides a la reparació de l’ADN potencia l’activitat antitumoral en #càncerdemamatriplenegatiu
➡️ linke.to/OmomycVHIO_Cat
@icreacommunity.bsky.social spin-off) amb teràpies dirigides a la reparació de l’ADN potencia l’activitat antitumoral en #càncerdemamatriplenegatiu
➡️ linke.to/OmomycVHIO_Cat
RRID:AB_2110945 from @proteintech.bsky.social was used by authors in their paper. Thanks for making your methods matter! #ReproducibleResearch #accelerateopenscience #ReproducibleResearch
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
doi.org
November 23, 2025 at 8:00 AM
RRID:AB_2110945 from @proteintech.bsky.social was used by authors in their paper. Thanks for making your methods matter! #ReproducibleResearch #accelerateopenscience #ReproducibleResearch
Un estudio liderado por Laura Soucek y Fabio Giuntini muestra que combinar el inhibidor de MYC Omomyc (de #Peptomyc, VHIO y
@icreacommunity.bsky.social spin-off) con terapias dirigidas a la reparación del ADN potencia la actividad antitumoral en #cáncerdemamatriplenegativo
➡️ linke.to/OmomycVHIO_C...
@icreacommunity.bsky.social spin-off) con terapias dirigidas a la reparación del ADN potencia la actividad antitumoral en #cáncerdemamatriplenegativo
➡️ linke.to/OmomycVHIO_C...
Combinar el inhibidor de MYC Omomyc con terapias dirigidas a la reparación del ADN potencia la respuesta antitumoral en
linke.to
December 2, 2025 at 11:51 AM
Un estudio liderado por Laura Soucek y Fabio Giuntini muestra que combinar el inhibidor de MYC Omomyc (de #Peptomyc, VHIO y
@icreacommunity.bsky.social spin-off) con terapias dirigidas a la reparación del ADN potencia la actividad antitumoral en #cáncerdemamatriplenegativo
➡️ linke.to/OmomycVHIO_C...
@icreacommunity.bsky.social spin-off) con terapias dirigidas a la reparación del ADN potencia la actividad antitumoral en #cáncerdemamatriplenegativo
➡️ linke.to/OmomycVHIO_C...
Enhorabona Laura Soucek per la subvenció #ProofOfConcept de l'@erc.europa.eu per al projecte #SONOMYC ‼️
🎯 Amb l'objectiu d'optimitzar l'administració de l'inhibidor de #MYC, Omomyc, al cervell per tractar tumors cerebrals i metàstasis.👉 https://linke.to/ERCLauraSoucek_VHIOCAT
#ERCPoC
🎯 Amb l'objectiu d'optimitzar l'administració de l'inhibidor de #MYC, Omomyc, al cervell per tractar tumors cerebrals i metàstasis.👉 https://linke.to/ERCLauraSoucek_VHIOCAT
#ERCPoC
July 14, 2025 at 10:15 AM
Enhorabona Laura Soucek per la subvenció #ProofOfConcept de l'@erc.europa.eu per al projecte #SONOMYC ‼️
🎯 Amb l'objectiu d'optimitzar l'administració de l'inhibidor de #MYC, Omomyc, al cervell per tractar tumors cerebrals i metàstasis.👉 https://linke.to/ERCLauraSoucek_VHIOCAT
#ERCPoC
🎯 Amb l'objectiu d'optimitzar l'administració de l'inhibidor de #MYC, Omomyc, al cervell per tractar tumors cerebrals i metàstasis.👉 https://linke.to/ERCLauraSoucek_VHIOCAT
#ERCPoC
Congrats to Laura Soucek for receiving the @erc.europa.eu #ProofOfConcept grant for #SONOMYC ‼️
🎯 The project aims to optimize the delivery of the #MYC inhibitor Omomyc to the brain to treat brain tumors & metastases 👉 https://linke.to/ERCLauraSoucek_VHIO
#ERCPoC.
🎯 The project aims to optimize the delivery of the #MYC inhibitor Omomyc to the brain to treat brain tumors & metastases 👉 https://linke.to/ERCLauraSoucek_VHIO
#ERCPoC.
July 14, 2025 at 10:02 AM
Congrats to Laura Soucek for receiving the @erc.europa.eu #ProofOfConcept grant for #SONOMYC ‼️
🎯 The project aims to optimize the delivery of the #MYC inhibitor Omomyc to the brain to treat brain tumors & metastases 👉 https://linke.to/ERCLauraSoucek_VHIO
#ERCPoC.
🎯 The project aims to optimize the delivery of the #MYC inhibitor Omomyc to the brain to treat brain tumors & metastases 👉 https://linke.to/ERCLauraSoucek_VHIO
#ERCPoC.
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer scientiasalut.gencat.cat/handle/11351... #ScientiaVH
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
scientiasalut.gencat.cat
April 27, 2026 at 8:01 AM
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer scientiasalut.gencat.cat/handle/11351... #ScientiaVH
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in #breast #cancer www.sciencedirect.com/science/arti... #hvhebron #onco [Text complet]
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA…
www.sciencedirect.com
November 26, 2025 at 11:28 AM
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in #breast #cancer www.sciencedirect.com/science/arti... #hvhebron #onco [Text complet]
Feed: "Medical Xpress - latest medical and health news stories"
Published on Tuesday, December 2, 2025
Published on Tuesday, December 2, 2025
Omomyc enhances PARP inhibitor effects and overcomes resistance in breast cancer models
Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a phase I clinical trial—causes DNA damage in cancer cells which is synergistical...
medicalxpress.com
December 3, 2025 at 2:56 AM
Feed: "Medical Xpress - latest medical and health news stories"
Published on Tuesday, December 2, 2025
Published on Tuesday, December 2, 2025
Found these, used to label Brainbow mice: https://www.cancertools.org/antibodies/155267?hsLang=en and https://www.cancertools.org/antibodies/155265?hsLang=en. Not sure how good they are?
Antibodies Archives
Discover and access Cancer research antibodies for use in your cancer research incl. Anti-Omomyc, UCH-T1, brainbow antibodies and many more
www.cancertools.org
January 4, 2025 at 8:41 PM
Found these, used to label Brainbow mice: https://www.cancertools.org/antibodies/155267?hsLang=en and https://www.cancertools.org/antibodies/155265?hsLang=en. Not sure how good they are?
Omomyc, a direct MYC inhibitor, enhances the effects of PARP inhibitors and overcomes resistance in preclinical models of triple-negative breast cancer. doi.org/hbdbvc
Omomyc enhances PARP inhibitor effects and overcomes resistance in breast cancer models
Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a phase I clinical trial—causes DNA damage in cancer cells which is synergistically enhanced in combination with poly (ADP-ribose) polymerase inhibitors (PARPi).
medicalxpress.com
December 2, 2025 at 9:05 PM
Omomyc, a direct MYC inhibitor, enhances the effects of PARP inhibitors and overcomes resistance in preclinical models of triple-negative breast cancer. doi.org/hbdbvc
Online now: ReCHEMbinant stapling enhances intracellular delivery and bioactivity of engineered protein inhibitors
ReCHEMbinant stapling enhances intracellular delivery and bioactivity of engineered protein inhibitors
ReCHEMbinant engineering enables chemical stapling of recombinant proteins to enhance their cellular uptake, serum stability, and general activity. Applying this strategy to the MYC inhibitor Omomyc produced HeloMYCs—synthetically enhanced variants that display potent intracellular activity and better cell penetration and MYC inhibition than the natural parent protein.
dlvr.it
December 17, 2025 at 4:34 PM
Online now: ReCHEMbinant stapling enhances intracellular delivery and bioactivity of engineered protein inhibitors